Skyline Licenses TrovaGene Biomarker for AML | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Skyline Diagnostics has licensed rights to TrovaGene's NPM1 technology in Europe in a microarray test for use in helping guide acute myelogenous leukemia treatment, TrovaGene said today.

Skyline will use the TrovaGene nucleophosmin protein mutation, which is found in around 35 percent of AML patients and is associated with good disease prognosis, in its AMLprofiler in vitro diagnostic assay.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: transcriptional and translational study of human cytomegalovirus interactions with host cells, spider web DNA study, and more.

The New York Stem Cell Foundation signs a lease for a new space.

Researchers gear up for an international meeting to discuss the ethics of gene editing.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.